Trial Profile
An Observational, Prospective Study to Evaluate the Hemoglobin Levels in Non-dialysis Chronic Kidney Disease Subjects With Renal Anaemia, Treated With MIRCERA (Methoxy-polyethylene-glycol-epoetin Beta) (OPTIMA)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2018
Price :
$35
*
At a glance
- Drugs Methoxy polyethylene glycol-epoetin beta (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Acronyms OPTIMA
- Sponsors Roche
- 01 Nov 2016 Status changed from active, no longer recruiting to completed.
- 01 Feb 2016 Status changed from recruiting to active, no longer recruiting, as reported by ClinicalTrials.gov record.
- 01 Jul 2015 Planned End Date changed from 1 Aug 2016 to 1 Oct 2016 as reported by ClinicalTrials.gov record.